| Abstract | The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based. |
| Authors | Zoltan Vajo
(Affiliation: University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. zoltanvajo at gmail.com)
|
| Journal | Expert review of vaccines
(Expert Rev Vaccines)
Vol. 8
Issue 5
Pg. 619-24
(May 2009)
ISSN: 1744-8395 [Electronic] England |
| PMID | 19397418
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Adjuvants, Immunologic
- Aluminum Compounds
- Influenza Vaccines
- Phosphates
- Vaccines, Inactivated
- aluminum phosphate
|
| Topics |
- Adjuvants, Immunologic
(pharmacology)
- Aluminum Compounds
(pharmacology)
- Disease Outbreaks
(prevention & control)
- Humans
- Hungary
- Influenza A Virus, H5N1 Subtype
(genetics, immunology)
- Influenza Vaccines
(adverse effects, genetics, immunology)
- Influenza, Human
(epidemiology, prevention & control)
- Phosphates
(pharmacology)
- Vaccines, Inactivated
(adverse effects, genetics, immunology)
|
